Provides therapy services to patients and develops medicines for central nervous system disorders including depression, chronic pain and PTSD.
10-K for FY2025, filed Mar 23, 2026
Commercial insurers, Medicare and patients pay for outpatient behavioral-health, interventional psychiatry and pain-management care. Procedures are charged when performed, while therapy and medication management are charged session by session; payment follows within one year of service.
10-K for FY2025, filed Mar 23, 2026The Company accounts for revenue under FASB ASC Topic 606, Revenue for Contract with Customers (ASC 606). Patient service revenue is…View ↗
Patient service revenue is primarily derived from services rendered to patients for outpatient behavioral health care, interventional…View ↗
The Company receives payments from the following sources: (i) commercial insurers; (ii) the federal government under the Medicare program…View ↗
10-K for FY2025, filed Mar 23, 2026
FY2025 revenue by product or service ↗$1.2M
10-K for FY2025, filed Mar 23, 2026
$1.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Procedures
Usage-based
10-K for FY2025, filed Mar 23, 2026 |
30% |
Procedures, FY2025
$371K Sources
|
Usage-based |
|
Therapy
Usage-based
10-K for FY2025, filed Mar 23, 2026 |
70% |
Therapy, FY2025
$854K Sources
|
Usage-based |
Patients receive outpatient behavioral-health, interventional psychiatry and pain-management services, with bills paid by commercial insurers, Medicare and individual patients.
10-K for FY2025, filed Mar 23, 2026
No. It lost $28.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 16, 2026
−$2.2MView ↗
10-Q for Q3 FY2026, filed Nov 16, 2026
Open tableView ↗
Adds patient-care services
The older report describes a clinical-stage drug developer; the latest also describes HOPE as a medical-services company providing interventional psychiatric care through clinics.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 23, 2026NRx is a clinical-stage pharmaceutical company which develops, through its wholly-owned operating subsidiary, NeuroRx, Inc., (“NeuroRx”)…View ↗
Adds a generic ketamine path The older report discusses ketamine as a candidate for treating severe bipolar depression; the latest describes a separate generic-approval route for preservative-free ketamine alongside an NDA route for depression treatment.
Loading...